Literature DB >> 24371780

Kinetics of del(7q) driven leukemogenesis in a patient with JAK2 V617F and TET2 mutated chronic myeloproliferative neoplasm.

Laura Laine Herborg1, Line Nederby1, Eigil Kjeldsen2, Kirsten Grønbæk3, Peter Hokland1, Maria Hansen1, Marcus Celik Hansen1, Anne Stidsholt Roug1.   

Abstract

Chronic myeloid neoplasms have susceptibility to transform into acute myeloid leukemia due to attainment of additional molecular lesions. We here describe the kinetics of a del(7q) driven leukemogenesis in a patient with multiple TET2 mutations and JAK2 V617F mutated chronic myeloproliferative neoplasm. The del(7q) emerged in the accelerated phase of disease, which was preceded by a lag phase of almost three years with normalized peripheral blood cell counts. Our results reveal that the del(7q), independently of other lesions, acts as a leukemic driver in this patient and that the stable long-lasting normalization of peripheral blood cell values concealed pending transformation.

Entities:  

Keywords:  Del(7q); Essential thrombocythemia; JAK2; TET2

Year:  2013        PMID: 24371780      PMCID: PMC3850390          DOI: 10.1016/j.lrr.2013.06.001

Source DB:  PubMed          Journal:  Leuk Res Rep        ISSN: 2213-0489


  11 in total

1.  Essential thrombocythemia versus early primary myelofibrosis: a multicenter study to validate the WHO classification.

Authors:  Jürgen Thiele; Hans Michael Kvasnicka; Leonhard Müllauer; Veronika Buxhofer-Ausch; Bettina Gisslinger; Heinz Gisslinger
Journal:  Blood       Date:  2011-03-29       Impact factor: 22.113

2.  TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis.

Authors:  Cyril Quivoron; Lucile Couronné; Véronique Della Valle; Cécile K Lopez; Isabelle Plo; Orianne Wagner-Ballon; Marcio Do Cruzeiro; Francois Delhommeau; Bertrand Arnulf; Marc-Henri Stern; Lucy Godley; Paule Opolon; Hervé Tilly; Eric Solary; Yannis Duffourd; Philippe Dessen; Hélène Merle-Beral; Florence Nguyen-Khac; Michaëla Fontenay; William Vainchenker; Christian Bastard; Thomas Mercher; Olivier A Bernard
Journal:  Cancer Cell       Date:  2011-06-30       Impact factor: 31.743

3.  Chromosomal abnormalities in transformed Ph-negative myeloproliferative neoplasms are associated to the transformation subtype and independent of JAK2 and the TET2 mutations.

Authors:  Florence Nguyen-Khac; Claude Lesty; Virginie Eclache; Lucile Couronné; Olivier Kosmider; Joris Andrieux; Marie-Agnes Collonge-Rame; Dominique Penther; Marina Lafage; Chrystele Bilhou-Nabera; Elise Chapiro; Marie-Joelle Mozziconacci; Francine Mugneret; Nathalie Gachard; Nathalie Nadal; Eric Lippert; Stephanie Struski; Nicole Dastugue; Christine Cabrol; Olivier A Bernard
Journal:  Genes Chromosomes Cancer       Date:  2010-10       Impact factor: 5.006

Review 4.  New mutations and pathogenesis of myeloproliferative neoplasms.

Authors:  William Vainchenker; François Delhommeau; Stefan N Constantinescu; Olivier A Bernard
Journal:  Blood       Date:  2011-06-07       Impact factor: 22.113

5.  Monosomy 7 and deletion 7q in children and adolescents with acute myeloid leukemia: an international retrospective study.

Authors:  Henrik Hasle; Todd A Alonzo; Anne Auvrignon; Catherine Behar; Myron Chang; Ursula Creutzig; Alexandra Fischer; Erik Forestier; Alcira Fynn; Oskar A Haas; Jochen Harbott; Christine J Harrison; Nyla A Heerema; Marry M van den Heuvel-Eibrink; Gertjan J L Kaspers; Franco Locatelli; Peter Noellke; Sophia Polychronopoulou; Yaddanapudi Ravindranath; Bassem Razzouk; Dirk Reinhardt; Natalia N Savva; Batia Stark; Stefan Suciu; Ichiro Tsukimoto; David K Webb; Dorora Wojcik; William G Woods; Martin Zimmermann; Charlotte M Niemeyer; Susana C Raimondi
Journal:  Blood       Date:  2007-02-13       Impact factor: 22.113

6.  Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm.

Authors:  Philip A Beer; François Delhommeau; Jean-Pierre LeCouédic; Mark A Dawson; Edwin Chen; David Bareford; Rajko Kusec; Mary Frances McMullin; Claire N Harrison; Alessandro M Vannucchi; William Vainchenker; Anthony R Green
Journal:  Blood       Date:  2009-12-11       Impact factor: 22.113

7.  TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis.

Authors:  A Tefferi; A Pardanani; K-H Lim; O Abdel-Wahab; T L Lasho; J Patel; N Gangat; C M Finke; S Schwager; A Mullally; C-Y Li; C A Hanson; R Mesa; O Bernard; F Delhommeau; W Vainchenker; D G Gilliland; R L Levine
Journal:  Leukemia       Date:  2009-03-05       Impact factor: 11.528

8.  Mutation in TET2 in myeloid cancers.

Authors:  François Delhommeau; Sabrina Dupont; Véronique Della Valle; Chloé James; Severine Trannoy; Aline Massé; Olivier Kosmider; Jean-Pierre Le Couedic; Fabienne Robert; Antonio Alberdi; Yann Lécluse; Isabelle Plo; François J Dreyfus; Christophe Marzac; Nicole Casadevall; Catherine Lacombe; Serge P Romana; Philippe Dessen; Jean Soulier; Franck Viguié; Michaela Fontenay; William Vainchenker; Olivier A Bernard
Journal:  N Engl J Med       Date:  2009-05-28       Impact factor: 91.245

9.  Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms.

Authors:  Franz X Schaub; Renate Looser; Sai Li; Hui Hao-Shen; Thomas Lehmann; Andre Tichelli; Radek C Skoda
Journal:  Blood       Date:  2010-01-08       Impact factor: 22.113

10.  Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation.

Authors:  Alexandre Theocharides; Marjorie Boissinot; François Girodon; Richard Garand; Soon-Siong Teo; Eric Lippert; Pascaline Talmant; Andre Tichelli; Sylvie Hermouet; Radek C Skoda
Journal:  Blood       Date:  2007-03-15       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.